Stockscreener 앱 받기
46.29
2.59%
-1.23
시장 영업 전:
47.28
0.99
+2.14%
Avidity Biosciences Inc 주식(RNA)의 최신 뉴스
The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal - MSN
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78 - 富途牛牛
Avidity (RNA) Gets 26% Jump on Potential Takeover - MSN
Chardan Capital Maintains "Buy" Rating for Avidity Biosciences with $75 Price Target - AInvest
Insider Selling at Avidity Biosciences: A Signal of Routine Tax Obligations or a Cause for Concern? - AInvest
Avidity Biosciences Insider Selling: Signal or Noise in a High-Potential Biotech Play? - AInvest
Avidity Biosciences Shares Slide 2.59% as 230M-Dollar Volume Ranks 431st Amid Analyst Optimism and Deepening Losses - AInvest
Novartis weighs deal for biotech Avidity Biosciences, FT reports - AOL.com
Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial Position - TipRanks
Avidity Biosciences: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $75 - AInvest
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $62 - 富途牛牛
Avidity Biosciences price target raised to $75 from $70 at Wells Fargo - TipRanks
Avidity Biosciences 2025 Q2 Earnings Significant Loss Widening Despite Revenue Surge - AInvest
Avidity (RNA) Q2 Revenue Jumps 88% - AOL.com
Avidity Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest - AInvest
Avidity Biosciences Signs Manufacturing Agreement with Lonza - TipRanks
Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c) - TipRanks
Earnings Flash (RNA) Avidity Biosciences, Inc. Reports Q2 Revenue $3.8M - MarketScreener
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights - PR Newswire
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium - MSN
Avidity Bio Climbs on Report of Novartis Takeover - MSN
Novartis eyes Avidity Biosciences in potential takeover: Report - Medical Dialogues
Rumour mill says Novartis may want to buy Avidity - pharmaphorum
Avidity Biosciences Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Novartis's Strategic Pursuit of Avidity Biosciences: A Catalyst for Biotech Value and Long-Term Growth? - AInvest
Avidity Biosciences Surges 26% on 877% Volume Spike to 121st Most Traded as High-Volume Stocks Outperform with 166% Returns - AInvest
- Yahoo Finance
Biote Corp. shares fall 13.21% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Avidity Biosciences: What’s Fueling its Surge? - timothysykes.com
Small Biotech Catapults On Rumored Novartis Takeover - Investor's Business Daily
Biote Corp. shares fall 6.74% after-hours as Novartis considers Avidity Biosciences acquisition. - AInvest
Celcuity Inc. shares rise 3.71% intraday as Novartis considers deal for biotech Avidity Biosciences. - AInvest
Avidity soars after rumours of Novartis' takeout interest emerge - FirstWord Pharma
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium By Stocktwits - Investing.com India
Novartis Eyes Avidity Biosciences in Potential Takeover BidNews and Statistics - IndexBox
Novartis Weighing Takeover Bid for Avidity Biosciences - MarketScreener
Avidity Biosciences Stock Soars Amidst Breakthrough Therapy Designation - StocksToTrade
Avidity Biosciences (RNA) Surges 22.6% on Novartis Takeover Rumors: Is This the Catalyst for a Biotech Breakout? - AInvest
Avidity Biosciences rises on report of Novartis buyout deal - TradingView
Novartis makes takeover approach for Avidity Biosciences, FT reports - TipRanks
Avidity Biosciences stock soars on Novartis takeover approach report By Investing.com - Investing.com South Africa
Avidity Biosciences stock soars on Novartis takeover approach report - Investing.com
Novartis weighs deal for biotech Avidity to boost drug pipeline - Financial Times
Avidity Biosciences RNA 2025Q2 Earnings Preview Downside Ahead on Increased Clinical Trial Spending - AInvest
Avidity Biosciences’ chief legal officer sells $81k in stock - Investing.com
Avidity Biosciences’ chief legal officer sells $81k in stock By Investing.com - Investing.com Canada
Why Avidity Biosciences (RNA) Is Up 8.0% After FDA Breakthrough and Phase 3 Milestones in Rare Disease - simplywall.st
Daily Turnover | The turnover of Avidity Biosciences on 8/4 was $107.25 Million, Ranking 835 - AInvest
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - ADVFN Brasil
Published on: 2025-08-04 08:12:22 - metal.it
What makes Avidity Biosciences Inc. stock price move sharplyDiscover market opportunities with expert help - Jammu Links News
What are analysts’ price targets for Avidity Biosciences Inc. in the next 12 monthsInvest confidently with daily market forecasts - Jammu Links News
How does Avidity Biosciences Inc. generate profit in a changing economyFree Capital Allocation Plans - Jammu Links News
What institutional investors are buying Avidity Biosciences Inc. stockAchieve breakthrough investment performance - Jammu Links News
Avidity Biosciences Inc. Stock Analysis and ForecastRobust investment performance - Jammu Links News
Is Avidity Biosciences Inc. a good long term investmentCapitalize on proven trading setups - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):